Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT04887493 |
| Other study ID # |
Sublingual misoprostol |
| Secondary ID |
IOL |
| Status |
Not yet recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
June 1, 2021 |
| Est. completion date |
November 30, 2021 |
Study information
| Verified date |
May 2021 |
| Source |
Ministry of Health, Bhutan |
| Contact |
Yeshey Dorjey, MS |
| Phone |
+97577293881 |
| Email |
yesheydorjey[@]gmail.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
This research is to compare the efficacy and the safety of sublingual misoprostol with
vaginal misoprostol administration for the induction of labour for primigravida at 41 or more
weeks of pregnancy. In routine practice, misoprostol 25µg is used by per vaginal route for
the induction of labour in Bhutan. The misoprostol dose is given repeatedly every 4 hours to
a maximum of 6 dosages. The per vaginal route is found to be very effective and safe for the
induction of labour. But, patient compliance is poor and increasing the risk of neonatal
sepsis since it has to be inserted into vagina every 4 hours. To overcome these problems with
per vaginal route, this study is developed to explore the efficacy and safety of misoprostol
use by sublingual routes for the induction of labour. Misoprostol can be used by sublingual,
oral or per vaginal route as per the findings of the other studies.
If the finding of this study proves sublingual use of misoprostol is safe and efficient for
the induction of labour, the current practice of using misoprostol by vaginal route will be
changed to sublingual route in Bhutan.
Description:
Induction of labour is an intervention intended to artificially initiate uterine contraction
in pregnant women who are not in labour. It is a common practice to interrupt the pregnancy
at 41 weeks of gestation and deliver the fetus when continuation of pregnancy is no longer
considered safe.
The methods of induction can be non-pharmacological or pharmacological. Prostaglandins and
oxytocin are the commonly used drugs for induction of labour.
Prostaglandins are the current drug of choice and have been used for labour induction in
pregnant women with an unfavourable cervix. Misoprostol is a synthetic analogue of
prostaglandin E1 and it has been extensively and successfully used for labour induction due
to its efficacy, low cost and stability at room temperature. Misoprostol can be used by oral,
vaginal or sublingual routes for the labour induction. Among which vaginal misoprostol has
been extensively used and shown to be an effective method of induction of labour. Sublingual
route of misoprostol is equally safe and effective for induction of labour. In fact,
sublingual route of misoprostol administration is found to be more effective in induction of
labour as compared to vaginal route. This sublingual route is appealing for several reasons,
including the convenience, easy to administer and a higher patient's acceptability. In
contrast to per vaginal misoprostol administration, sublingual route avoids repeated per
vaginal examination which is a risk factor for neonatal sepsis.
In Bhutan per vaginal misoprostol is being extensively used for induction of labour by the
Gynecologists. The neonatal sepsis rate is 19 per 1000 in Bhutan, which is the highest in
Asia. The high rate of neonatal sepsis in Bhutan is found to be associated with repeated
vaginal examination done during pregnancy to administer misoprostol dose.
No study has been conducted in Bhutan to find out the safety and efficacy of per vaginal
misoprostol use nor is there any study on sublingual use of misoprostol for the induction of
labour.
Therefore, this study is developed to explore whether sublingual misoprostol may be tried as
a new option for induction of labour comparing the efficacy of administration of sublingual
misoprostol with vaginal misoprostol for induction of labour at term and post term
pregnancies.
This will be a randomized clinical trial with a parallel design (simple randomization).
The study will be conducted in Phuentsholing General Hospital, Chukha, Bhutan.
The study duration will be six months starting from 1st June to 30th November 2021.
For the study, all the primigravida at 41 or more weeks of pregnancy admitted to Gynecology
ward, Phuentsholing hospital will be approached to participate.
Primigravid pregnant women who have consented voluntarily will be recruited for the study.
The study population will randomly put into two groups by simple randomization as follows:
Group 1- To induce the labor with misoprostol 25µg sublingually; Group 2- To induce the labor
with misoprostol 25µg per vaginally.
The researchers and the study participants will not be blinded; however, the statisticians
who will analyze the data will be blinded to avoid possible bias in drawing the inferences.
Sample size is calculated based on the finding of previous study which had reported with a
statistically significant difference of mean induction to delivery interval between
sublingual group and per vaginal use of misoprostol group (P<0.001). The mean induction to
delivery interval of 13.1±4.1 hours for sublingual group as compared to 17.9±5.4 hours for
vaginal group(21). With 5% error and 80% power, sample size is determined by using PASS
(Power Analysis and Sample Size Software) 2021 software.
The total sample size is 24 from the calculation using the previous research finding.
Therefore, the current research will recruit 20 study participants in each group; group 1
(n=20), and group 2 (n=20).
Sampling technique will be a non-purposive sampling.
Written informed consent will be obtained from the participants.
After obtaining ethical clearance from the Research Ethical Board of Health (REBH), Ministry
of Health, Thimphu, Bhutan; pregnant women who are admitted to gynecology ward for induction
of labor for various reasons will be approached and will take detailed history, review
previous medical documents, and conduct relevant general and obstetrical examination. This
procedure will be done to ensure correct dating of pregnancy (to avoid inducing preterm), to
re-confirm the indications for induction of labor and to exclude contraindications for
vaginal delivery. Primigravid pregnant women at 41 or more weeks of pregnancy will be
counseled and explained about the research purpose, objectives, methods, outcomes and the
benefits. If they are willing to participate in the research, the written informed consent
will be obtained. Eligibility criteria will be applied and the pregnant mothers who fulfill
the inclusion criteria will be recruited for the study from 1st June to 30th November 2021.
The enrolled pregnant women will then be randomly allocated in two groups by lottery methods.
Enrolled pregnant mothers will be asked to pick up a rolled paper from the lottery box which
will determine the study group of the subject. The group-1 will receives misoprostol 25µg by
sublingual route and group-2 will receives misoprostol 25µg by vaginal route. Sublingual
route involves placing misoprostol in the sublingual space under the tongue and the vaginal
route involves placing misoprostol inside the posterior fornix of vagina.
Prior to starting the first dose of misoprostol administration, cardiotocography (CTG) will
be done to ensure fetal heart rate tracing is reassuring and per vaginal examination will be
done to assess the Bishop's score in both the groups.
Per vaginal examination will be done by a female nurse maintaining optimum privacy. If the
fetal heart rate is reassuring and the Bishop's score is unfavorable, then induction of labor
with misoprostol will commence. Both groups will receive repeat dose of misoprostol 25µg
every 4 hours up to a maximum of 6 dosages. The drug will be administered sublingually or
vaginally according to the allocated group by the female nurse.
Pregnant women will never be left unattended once the induction of labor has started. Close
monitoring of fetal heart rate and uterine activity will be done for 30 minutes after every
dose of misoprostol for both the study group. This is to look for changes in fetal heart rate
and for early detection of rare occurrence of uterine hyperstimulation with the peak
concentration of misoprostol in the circulation. If there is uterine hyperstimulation
(presence of five or more contractions per 10 minutes for at least 20 minutes) patient will
be monitored with continuous CTG, put patient on left lateral position, give oxygen
(8-10L/min) and hydrate with IV fluids. If hyperstimulation fails to resolve and the abnormal
fetal heart rate persists (absence of acceleration, presence of late or variable
deceleration, reduced variability, bradycardia or tachycardia) Inj. salbutamol 100 µg IV over
1-2 minute will be given. If CTG remains suggestive of fetal compromise despite the
management for hyperstimulation, pregnancy will be terminated by emergency caesarean section.
Prior to repeating the misoprostol dose, repeat CTG will be done to ensure reassuring fetal
heart rate tracing in both the groups. For group 2 per vaginal examination will be done every
4 hours to assess Bishop score and to give a repeat dose of misoprostol per vaginal route.
For group 1, repeated per vaginal examination will not be done, rather repeat misoprostol
dose will be placed in the sublingual space under the tongue. The repeat misoprostol dose
will be administered only if fetal heart rate tracing is reassuring and there is no uterine
contraction or labor pain. If the fetal heart rate tracing is non-reassuring (fetal
distress), the repeat dose of misoprostol will be withheld and pregnant mothers will be put
to left lateral position, IV fluids (crystalloids) will be given to hydrate, oxygen will be
administered by face mask at 6-10L/min and CTG will be repeated after 30minutes. If the fetal
heart rate tracing is still non-reassuring (features of fetal distress persists) even after
managing with hydration and oxygen administration, pregnancy will be terminated by emergency
caesarean section.
If fetal heart rate tracing returns to reassuring status after hydration and oxygenation, the
misoprostol dose will be restarted. Once the uterine contraction or labor pain starts, the
repeat dose of misoprostol will be withheld and per vaginal examination will be done for both
the study groups to assess the Bishop score. Once the cervix becomes ripe or the Bishop score
is favorable, and in absence of uterine contraction or labour pain, induction with oxytocin
will be done after 4 hours of the last dose of misoprostol administration.
Once the patient is in active labor, augmentation with oxytocin will be done if there is
inadequate uterine contraction. Labor process will be closely monitored for progression of
labor and to assess fetal and maternal conditions using partograph. Routine active management
of the third stage of labor will be done.
Newborn will be assessed for Apgar score at 1 minute and again at 5 minutes after birth.
In both the study groups if labor fails to get induced even after 6 dosages of misoprostol
(failed induction), and if Bishop score is unfavorable; induction with Foley's catheter will
be offered to the pregnant mother. Foley's catheter (16F) will be placed by transcervically
and inflate the balloon with 30-50 ml of water. Unless balloon expels out it is kept in situ
for 12 hours. After 12 hours Foley's catheter will be removed by deflating the balloon. If
the labour fails to get induced or the Bishop score is unfavorable even after the mechanical
induction with Foley's catheter, pregnancy will be terminated by caesarean section.
After the delivering the baby, and when mothers are free of pain, they will be asked to give
a rating on the satisfaction score scale on the induction of labour route they received.
The interviewer administered pre-tested questionnaire will be used to collect the data.
Pre-testing of the questionnaire will be done to the gynecology ward nursing staff.
Primary outcome is to measure the number of pregnant mothers who have a vaginal delivery
within 24 hours of the induction.
Secondary outcomes are; to find out the time taken from induction to delivery, to find out
the total dosages of misoprostol required for induction, to find out the maternal and
neonatal outcomes, to measure the satisfaction score and to analyze the Apgar score at birth.
The study proposal is submitted to the Research Ethical Board of Health (REBH), Ministry of
Health, Thimphu, for ethical clearance and an expedited review. The research will commence
only after obtaining ethical clearance.
The collected data will be captured and double entered using Epidata 3.1.2 (Odense, Denmark)
and validated to avoid data entry errors. The data will then be exported to SPSS format for
further analysis. The data will be analyzed using SPSS version 23. Descriptive statistics
commands such as frequencies, percentages, mean, median, confidence interval, and standard
deviation will be used to describe the study variables. The Chi-square test will be used for
categorical variables outcome variables. Student's t-test will be employed for A p value
<0.05 will be considered statistically significant with confidence interval of 95%.
